Literature DB >> 33838042

No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: A Mendelian randomization study.

Liu Miao1, Guo-Xiong Deng1, Rui-Xing Yin1,2,3, Rong-Jun Nie1, Shuo Yang1, Yong Wang4, Hui Li5.   

Abstract

BACKGROUND: Although many observational studies have shown an association between plasma homocysteine levels and cardiovascular diseases, controversy remains. In this study, we estimated the role of increased plasma homocysteine levels on the etiology of coronary heart disease and acute myocardial infarction.
METHODS: A two-sample Mendelian randomization study on disease was conducted, i.e. "coronary heart disease" (n = 184,305) and "acute myocardial infarction" (n = 181,875). Nine single nucleotide polymorphisms, which were genome-wide significantly associated with plasma homocysteine levels in 57,644 subjects from the Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics (CARDIoGRAMplusC4D) consortium genome-wide association study and were known to be associated at p < 5×10-8, were used as an instrumental variable.
RESULTS: None of the nine single nucleotide polymorphisms were associated with coronary heart disease or acute myocardial infarction (p > 0.05 for all). Mendelian randomization analysis revealed no causal effects of plasma homocysteine levels, either on coronary heart disease (inverse variance weighted; odds ratio = 1.015, 95% confidence interval = 0.923-1.106, p = 0.752) or on acute myocardial infarction (inverse variance weighted; odds ratio = 1.037, 95% confidence interval = 0.932-1.142, p = 0.499). The results were consistent in sensitivity analyses using the weighted median and Mendelian randomization-Egger methods, and no directional pleiotropy (p = 0.213 for coronary heart disease and p = 0.343 for acute myocardial infarction) was observed. Sensitivity analyses confirmed that plasma homocysteine levels were not significantly associated with coronary heart disease or acute myocardial infarction.
CONCLUSIONS: The findings from this Mendelian randomization study indicate no causal relationship between plasma homocysteine levels and coronary heart disease or acute myocardial infarction. Conflicting findings from observational studies might have resulted from residual confounding or reverse causation. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Two-sample mendelian randomization; acute myocardial infarction; causation; coronary heart disease; genome-wide association study; plasma homocysteine levels

Mesh:

Substances:

Year:  2019        PMID: 33838042     DOI: 10.1177/2047487319894679

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  5 in total

Review 1.  The Link between Homocysteine and Omega-3 Polyunsaturated Fatty Acid: Critical Appraisal and Future Directions.

Authors:  Gianluca Rizzo; Antonio Simone Laganà
Journal:  Biomolecules       Date:  2020-02-02

2.  Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study.

Authors:  Shuai Yuan; Amy M Mason; Paul Carter; Stephen Burgess; Susanna C Larsson
Journal:  BMC Med       Date:  2021-04-23       Impact factor: 11.150

3.  Causal Relationships Between Total Physical Activity and Ankylosing Spondylitis: A Mendelian Randomization Study.

Authors:  Shaojun Hu; Hongyuan Xing; Xingchen Wang; Ning Zhang; Qiang Xu
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

Review 4.  Abnormal Homocysteine Metabolism: An Insight of Alzheimer's Disease from DNA Methylation.

Authors:  Tingting Pi; Bo Liu; Jingshan Shi
Journal:  Behav Neurol       Date:  2020-09-08       Impact factor: 3.342

5.  Causal effect between total cholesterol and HDL cholesterol as risk factors for chronic kidney disease: a mendelian randomization study.

Authors:  Liu Miao; Yan Min; Bin Qi; Chuan-Meng Zhu; Jian-Hong Chen; Guo-Xiong Deng; Yong Wang; Jian-Fei Li; Rong-Shan Li
Journal:  BMC Nephrol       Date:  2021-01-20       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.